Raising the Bar by Lowering the Target
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
American College of Cardiology Scientific Sessions & Expo
March 2018; Orlando, Florida.
Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY Outcomes trial.
Steg P, et al. American College of Cardiology Scientific Sessions & Expo; March 2018; Orlando, FL. Late-Breaking Clinical Trial Session 401-08.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG, et al. Am Heart J. 2014;168(5):682-689.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.
Sabatine MS, et al. Am. Heart J. 2016;173:94-101.
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Goldberg AC, et al. J Clin Lipidol. 2011;5(suppl 3):S1-S8.
Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG. J Manag Care Pharm. 2013;19(2):139-149.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, et al. N Engl J Med. 2015;372(16):1489-1499.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS, et al. N Engl J Med. 2015;372(16):1500-1509.
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
Zhang XL, et al. BMC Med. 2015;13(123):1-18.
Clinical Practice Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Stone NJ, et al. Circulation. 2014;129(25 suppl 2):S1-S45.
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report.
Jacobson TA, et al. J Clin Lipidol. 2015;9(2):129-169.
2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Lloyd-Jones DM, et al. J Am Coll Cardiol. 2016;68(1):92-125.
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM, et al.J Am Coll Cardiol. 2017;70(14):1785-1822.
Recent Update to the US Cholesterol Treatment Guidelines A Comparison With International Guidelines.
Nayor M, Vasan RS. Circulation. 2016;133(18):1795-1806.
Clinical Assessment Tools
ASCVD Risk Estimator
A companion tool to the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk and the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Goff DC, et al. J Am Coll Cardiol. 2014;633(25 Pt B):2935-2959 and Goff DC, et al. Circulation. 2014:129(25 suppl 2):S49-S73).
Reynolds Risk Score
A framework for calculating heart and stroke risk for women and men (Ridker PM, et al. JAMA. 2007;297(6):611-619).
Patient Resources
Centers for Disease Control and Prevention
Educational materials for patients with high cholesterol.
American Heart Association
Resources on managing hyperlipidemia by controlling cholesterol and triglycerides.
The FH Foundation
A patient-centered nonprofit organization dedicated to education, advocacy, and research on familial hypercholesterolemia (FH).
Hot Topics in Dyslipidemia
From the 2018 American College of Cardiology Scientific Sessions
| Faculty: | Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD |
| Release: | 04/04/2018 |
| Expiration: | 04/04/2019 |
Individualizing LDL-C Targets in High-Risk Patients
Module 2
| Faculty: | Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH |
| Release: | 08/15/2018 |
| Expiration: | 08/14/2019 |
Novel Nonstatin LDL-C Targets in High-Risk Patients
Module 3
| Faculty: | Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH |
| Release: | 08/14/2018 |
| Expiration: | 08/14/2019 |
Long-term Cardiovascular Outcomes Trials With PCKS9 Inhibitors
Module 4
| Faculty: | Christie M. Ballantyne, MD, FACP, FACC; Marc S. Sabatine, MD, MPH |
| Release: | 08/13/2018 |
| Expiration: | 08/14/2019 |
Collaborating with Patients to Reduce Long-Term Hypercholesterolemia Risks
Module 5
| Faculty: | Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD; |
| Release: | 10/22/2018 |
| Expiration: | 10/22/2019 |
Tailored Lipid-Lowering Regiments for Specific Very High-Risk Profiles
Module 6
| Faculty: | Christopher P. Cannon, MD; Sergio Fazio, MD, PhD |
| Release: | 10/22/2018 |
| Expiration: | 10/22/2019 |
Pharmacoeconomic Outcomes of Suboptimal LDL-C Management
Module 7
| Faculty: | Deepak L. Bhatt, MD, MPH; Sergio Fazio, MD, PhD |
| Release: | 10/22/2018 |
| Expiration: | 10/22/2019 |
Raising the Bar by Lowering the Target
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
| Faculty: | Christie M. Ballantyne, MD, FACP, FACC; Deepak L. Bhatt, MD, MPH; Christopher P. Cannon, MD; Sergio Fazio, MD, PhD |
| Release: | 11/28/2018 |
| Expiration: | 11/28/2019 |
